Remaining offer shares registered with Finnish Trade Register
Faron Pharmaceuticals Ltd. has registered the remaining 41,944,771 offer shares with the Finnish Trade Register, bringing the total registered shares to 203,045,511, with 199,514,938 voting rights after accounting for treasury shares. These remaining shares are expected to be available in investors' book-entry accounts around April 15, 2026, and trading on Nasdaq First North Growth Market Finland and AIM is anticipated to commence on or about the same date.
Select text to share a quote on X · sign in to keep highlights & notes in your FARN notes
| Faron Pharmaceuticals Ltd | Company announcement | April 14, 2026 at 15:15:00 EEST |
Faron Pharmaceuticals Ltd: Remaining offer shares registered with Finnish Trade Register
TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON, “Faron” or the “Company”) announced on 9 April 2026 results of the share offering (the “Offering“) consisting of 80,158,126 offer shares (the “Offer Shares”). Faron has today registered with the Trade Register maintained by the Patent and Registration Office the remaining 41,944,771 Offer Shares, which were allocated to the primary and secondary subscribers (“Remaining Offer Shares”).
Following the registration of the Remaining Offer Shares, the total number of registered shares in Faron is 203,045,511. Shares held in treasury by the Company do not confer a right to dividends or other shareholder rights. The Company holds 3,530,573 shares in treasury and therefore, the total number of voting rights in Faron is 199,514,938 (the “Number of Shares and Votes”). This figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify an interest in, or a change to their interest in, the Number of Shares and Votes of the Company.
The Remaining Offer Shares are expected to be recorded on investors' book-entry accounts on or about 15 April 2026. Applications have been made for the admission to trading of the Remaining Offer Shares on the Nasdaq First North Growth Market Finland (“First North“) maintained by Nasdaq Helsinki Ltd (“Nasdaq Helsinki“) under the current trading code “FARON”, and on AIM (“AIM“), the market of that name operated by London Stock Exchange plc under the trading code “FARN”. Trading in the Remaining Offer Shares on First North and in the Offer DIs on AIM is expected to commence on First North and AIM on or about 15 April 2026 subject to the admission of the Remaining Offer Shares to trading on First North and AIM.
Faron Pharmaceuticals Ltd
About bexmarilimab
Caution regarding forward-looking statements
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.